# OnCo record paper-gross-neoadjuvant-cemiplimab-cscc-nejm-2022 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-gross-neoadjuvant-cemiplimab-cscc-nejm-2022/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-gross-neoadjuvant-cemiplimab-cscc-nejm-2022" ;
  schema:name "Neoadjuvant cemiplimab for stage II to IV cutaneous squamous cell carcinoma"@en ;
  schema:description "Giving four doses of cemiplimab before surgery for resectable cutaneous squamous cell carcinoma eliminated all viable tumour in half of patients and left only minimal residual disease in another 13 percent, opening the way to smaller operations and less radiotherapy."@en ;
  schema:url <https://onco.cc/key-papers/paper-gross-neoadjuvant-cemiplimab-cscc-nejm-2022/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:citation <https://doi.org/10.1056/NEJMoa2209813>, <https://pubmed.ncbi.nlm.nih.gov/36094839/> ;
  schema:sameAs <https://doi.org/10.1056/NEJMoa2209813> ;
  schema:datePublished "2022"^^xsd:gYear ;
  schema:author "Gross ND, Miller DM, Khushalani NI, et al." ;
  onco:cancers <https://onco.cc/cancers/advanced-cutaneous-scc/> ;
  onco:drugs <https://onco.cc/drugs/cemiplimab/> ;
  onco:journals <https://onco.cc/journals/nejm/> .